Current Atherosclerosis Reports

, Volume 7, Issue 5, pp 351–357

Statins and proteinuria

  • Donald G. Vidt
Article

Abstract

The proteinuria associated with 3-hydrodoxy-3-methylglutaryl coenzyme A reductase inhibitors is composed of primarily low-molecular weight proteins that disappear rapidly following discontinuation of the statin agent. More importantly, no evidence exists of nephrotoxicity or reduced renal function observed with the approved clinical dosages of any available statins. Recent clinical studies have suggested actual improvement in renal function demonstrated by decreases in creatinine concentrations and improvement in estimated glomerular filtration rates with both short-term and long-term administration of these agents. The progressive fibrosis and renal scarring of chronic kidney disease appears to be the end result of increased protein traffic in the proximal renal tubule. Early animal and recent clinical studies have suggested that treatment with statin agents in established chronic kidney disease can, in fact, provide renoprotection over and above that observed with aggressive blood pressure control and the use of angiotensin II antagonists.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Oliver J, MacDowell M, Lee YC: Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins. J Exp Med 1954, 99:589–604.PubMedCrossRefGoogle Scholar
  2. 2.
    Straus W: Cytochemical investigation of phagosomes and related structures in cryostat sections of the kidney and liver of rats after intravenous administration of horseradish peroxidase. Exp Cell Res 1962, 27:80–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Novikoff AB: The rat kidney; cytochemical and electron microscopic studies. In Ciba Foundation Symposium, Edited by Quinn EL, Kass EK. Boston: Little, Brown; 1960; 113–144.Google Scholar
  4. 4.
    Christensen EI, Nielsen S: Structural and functional features of protein handling in the kidney proximal tubule. Semin Nephrol 1991, 11:414–439.PubMedGoogle Scholar
  5. 5.
    Maack T: Renal filtration, transport and metabolism of protein. In The Kidney, edn 3. Edited by Seldin DW, Giebish G. Philadelphia: Lippincott, Williams & Wilkins; 2000: 2235–2267.Google Scholar
  6. 6.
    Clague MJ: Molecular aspects of the endocytic pathway. Biochem J 1998, 336(Pt 2):271–282.PubMedGoogle Scholar
  7. 7.
    Wall DA, Maack T: Endocytic uptake, transport, and catabolism of proteins by epithelial cells. Am J Physiol 1985, 248:C12-C20.PubMedGoogle Scholar
  8. 8.
    Christensen EI, Birn H: Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001, 280:F562-F573.PubMedGoogle Scholar
  9. 9.
    Christensen EI, Birn H, Verroust P, Moestrup SK: Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998, 180:237–284.PubMedGoogle Scholar
  10. 10.
    Agarwal R: Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004, 15:2502–2503.PubMedCrossRefGoogle Scholar
  11. 11.
    Brunskill NJ, Cockcroft N, Nahorski S, Walls J: Albumin endocytosis is regulated by heterotrimeric GTP-binding protein G alpha i-3 in opossum kidney cells. Am J Physiol 1996, 271:F356-F364.PubMedGoogle Scholar
  12. 12.
    Leheste JR, Rolinski B, Vorum H, et al.: Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999, 155:1361–1370.PubMedGoogle Scholar
  13. 13.
    Vidt DG, Cressman MD, Harris S, et al.: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Schwegler JS, Heppelmann B, Mildenberger S, Silbernagl S: Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: a model for proximal tubular protein reabsorption. Pflugers Arch 1991, 418:383–392.PubMedCrossRefGoogle Scholar
  15. 15.
    Sidaway JE, Davidson RG, McTaggart F, et al.: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004, 15:2258–2265.PubMedCrossRefGoogle Scholar
  16. 16.
    Verhulst A, D’Haese PC, De Broe ME: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004, 15:2249–2257.PubMedCrossRefGoogle Scholar
  17. 17.
    Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-GoA reductase inhibitor, in healthy subjects, Br J Clin Pharmacol 1990, 29:239–243.PubMedGoogle Scholar
  18. 18.
    Martin PD, Warwick MJ, Dane AL, et al.: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003, 25:2553–2563.PubMedCrossRefGoogle Scholar
  19. 19.
    Endocrinologic and Metabolic Drugs Advisory Committee, July 9 2003, Food and Drug Administration Center for Drug Evaluation and Research. Department of Health and Human Services. 2003, Available at http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.doc. Accessed July 5, 2004.Google Scholar
  20. 20.
    Pharmacology/Toxicology. DNA 21-366 Crestor July 9, 2003. Advisory Committee Briefing Document. Department of Health and Human Services. 2004. Available at http://www.fda.gov.ohrms/dockets/ac/03/briefing/3968B1 02 F-FDA-Pharm Tox%20Review.pdf. Accessed on July 5, 2004.Google Scholar
  21. 21.
    Tonelli M, Moye L, Sacks FM, et al.: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98–104.PubMedGoogle Scholar
  22. 22.
    Heart Protection Study Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.CrossRefGoogle Scholar
  23. 23.
    Collins R, Armitage J, Parish S, et al., for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016.PubMedCrossRefGoogle Scholar
  24. 24.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation GREACE. study. J Clin Pathol 2004, 57:728–734.PubMedCrossRefGoogle Scholar
  25. 25.
    Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002, 136:604–615.PubMedGoogle Scholar
  26. 26.
    Zoja C, Donadelli R, Colleoni S, et al.: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation, Kidney Int 1998, 53:1608–1615.PubMedCrossRefGoogle Scholar
  27. 27.
    Orisio S, Benigni A, Bruzzi I, et al.: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993, 43:354–358.PubMedGoogle Scholar
  28. 28.
    Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995, 47:1546–1557.PubMedCrossRefGoogle Scholar
  29. 29.
    Remuzzi G: Nephropathic nature of proteinuria. Curr Opin Nephrol Hypertens 1999, 8:665–663.CrossRefGoogle Scholar
  30. 30.
    Comper WD, Osicka TM: Albumin-like material in urine. Kidney Int Suppl 2004, S65–S66.Google Scholar
  31. 31.
    Eppel GA, Osicka TM, Pratt LM, et al.: The return of glomerular filtered albumin to the rat renal vein—the albumin retrieval pathway. Renal Fail 2001, 23:347–363.CrossRefGoogle Scholar
  32. 32.
    Wharram BL, Goyal M, Gillespie PJ, et al.: Altered podocyte structure in GLEPP1 Ptpro.-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000, 106:1281–1290.PubMedCrossRefGoogle Scholar
  33. 33.
    Hara M, Yanagihara T, Takada T, et al.: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998, 18:35–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Nakamura T, Ushiyama C, Suzuki S, et al.: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379–1383.PubMedCrossRefGoogle Scholar
  35. 35.
    Kriz W, LeHir M: Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005, 67:404–419.PubMedCrossRefGoogle Scholar
  36. 36.
    Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799–812.PubMedCrossRefGoogle Scholar
  37. 37.
    Brouhard BH, Takamori H, Satoh S, et al.: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 1994, 8:436–440.PubMedCrossRefGoogle Scholar
  38. 38.
    Inman SR, Stowe NT, Cressman MD, et al.: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999, 317:215–221.PubMedCrossRefGoogle Scholar
  39. 39.
    Liang K, Vaziri ND: HMG-CoA reductase inhibition with rosuvastatin improves hyperlipidemia and proteinuria and reverses LDL receptor and HDL receptor deficiencies in the nephrotic syndrome [abstract]. J Am Soc Nephrol 2003, 14:168A.Google Scholar
  40. 40.
    Usui H, Shikata K, Matsuda M, et al.: HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003, 18:265–272.PubMedCrossRefGoogle Scholar
  41. 41.
    Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260–269.PubMedCrossRefGoogle Scholar
  42. 42.
    Bianchi S, Bigazzi R, Ciazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003, 41:565–570.PubMedCrossRefGoogle Scholar
  43. 43.
    Lee TM, Su SF, Tsai CH: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002, 40:67–73.PubMedCrossRefGoogle Scholar
  44. 44.
    Tonolo G, Melis MG, Formato M, et al.: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000, 30:980–987.PubMedCrossRefGoogle Scholar
  45. 45.
    Perkins BA, Ficociello LH, Silva KH, et al.: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285–2293.PubMedCrossRefGoogle Scholar
  46. 46.
    Adam A, Raij L: Nitric oxide—angiotensin II axis in renal and cardiovascular injury. J Nephrol 2000, 13:211–220.PubMedGoogle Scholar
  47. 47.
    Kurose I, Wolf R, Grisham MB, Granger DN: Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 1994, 74:376–382.PubMedGoogle Scholar
  48. 48.
    Tesfamariam B, Frohlich BH, Gregg RE: Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999, 34:95–101.PubMedCrossRefGoogle Scholar
  49. 49.
    Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins lovastatin or pravastatin. in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors enalapril or lisinopril. Am J Cardiol 1999, 83:1497–1499.PubMedCrossRefGoogle Scholar
  50. 50.
    Ikeda T, Sakurai J, Nakayama D, et al.: Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004, 17:502–506.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Donald G. Vidt
    • 1
  1. 1.Department of Nephrology & HypertensionCleveland Clinic FoundationClevelandUSA

Personalised recommendations